Six Hicks Thomas Lawyers Named to Lawdragon's 500 X – The Next Generation List
This year's honorees include D. Ryan Cordell, Jr., Allison Fisher, Jessica K. Little, , Aleza Remis, and Jessica Wahl. Their selection across six commercial litigation categories reflects the depth and range of the firm's litigation practice.
'This recognition reflects the caliber of young lawyers we're fortunate to have at Hicks Thomas,' said partner John B. Thomas. 'These lawyers are already delivering meaningful results for clients, and we expect them to play a key role in the firm's continued growth.'
Mr. Cordell, who was recognized for mass torts and personal injury litigation excellence, is a three-time "Next Generation" honoree. He handles cases involving contract disputes, tortious business conduct, trade secret misappropriation, and intellectual property infringement.
Ms. Fisher, a first-time honoree for environmental law, also focuses on personal injury and business litigation. A three-time Super Lawyers Rising Stars honoree, her legal experience is augmented by management experience at theater organizations around the country.
Ms. Little is honored for excellence in health care representation. She handles cases involving energy, technology, drug testing, financial services, consumer products, and the food industry as well. Her work has also been recognized by The Best Lawyers in America for four consecutive years.
Ms. Medrano was named to the Lawdragon list for expertise in managed care litigation. In addition to advising clients on issues involving medical benefits, she deals with insurance coverage, insurance defense, and business and commercial disputes.
Ms. Remis, who as a federal prosecutor led the Justice Department's Texas Health Care Fraud Strike Force, is also a first-time honoree for health care litigation. Her work includes cases involving Medicare, Medicaid, and private insurance fraud, in addition to civil cases falling under the False Claims Act.
Ms. Wahl, the firm's fifth first-time Lawdragon 500 X honoree, was recognized in the emerging data privacy sector. She also handles a wide range of cases involving commercial and contract disputes, product liability, mass torts, and environmental litigation.
Lawdragon selects honorees through nominations, independent research, and peer recommendations. See the full list here.
Founded in 1997, Texas-based Hicks Thomas LLP is a premier litigation firm representing plaintiffs and defendants across the nation. With offices in Houston, Austin, Beaumont, Amarillo, and Sacramento, California, the firm provides in-depth experience in cases involving oil and gas (upstream, midstream and downstream), construction, environmental, complex commercial, toxic tort, products liability, corporate governance, securities, banking, insurance coverage, transportation, trade secrets and general business litigation. Learn more: http://www.hicks-thomas.com.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
27 minutes ago
- Business Wire
Advicenne Receives Marketing Authorization and Reimbursement for Sibnayal® in Saudi Arabia
PARIS--(BUSINESS WIRE)--Regulatory News: Advicenne (Euronext Growth® - FR0013296746 - ALDVI), a pharmaceutical company specializing in the development and marketing of innovative treatments for people suffering from rare kidney diseases, obtains marketing authorization (MA) and reimbursement status for Sibnayal® (a fixed combination of potassium citrate and potassium bicarbonate) in the Kingdom of Saudi Arabia (KSA). Marketing authorization for Sibnayal® (ADV7103) in distal Renal Tubular Acidosis (dRTA) in KSA has been granted, based on the European registration dossier. Furthermore, Saudi authorities have agreed a reimbursement rate in line with the best European pricing. This achievment results of a close collaboration between Advicenne and its local partner, Taïba Healthcare, a leading distributor of pharmaceutical products in the Gulf region. Advicenne will act as the marketing authorization holder, while Taïba Healthcare will manage local marketing activities. The incidence of dRTA is higher in Gulf countries than in Europe or the United States, and prevalence in KSA could be estimated around 600 to 800 patients. Sibnayal® is already prescribed through early access programs in several Gulf countries outside Saudi Arabia. This milestone paves the way for registrations in GCC countries where the application is filed. Didier Laurens, CEO of Advicenne, declared: 'I am particularly proud of this important achievement and wish to congratulate both Advicenne and Taïba Healthcare teams, whose efforts were instrumental in informing and convincing the Saudi health authorities. The reimbursement obtained, comparable to the highest levels recorded in Europe, further attests to the significant therapeutic value of Sibnayal® in a region with one of the highest prevalence rates of dRTA worldwide.' About Advicenne Advicenne (Euronext: ALDVI) is a specialty pharmaceutical company founded in 2007, specializing in the development of innovative treatments in Nephrology. Its lead product Sibnayal® (ADV7103) has received its Marketing Approval for distal renal tubular acidosis in EU and GB. ADV7103 is currently in late-stage development in cystinuria in Europe and in dRTA and cystinuria in the US and in Canada. Headquartered in Paris, Advicenne, listed on the Euronext Paris stock exchange since 2017, has now been listed on Euronext Growth Paris since its transfer on March 30, 2022. For additional information, see: Disclaimer This press release contains certain forward-looking statements concerning Advicenne group and its business, including its prospects and product candidate development. Such forward-looking statements are based on assumptions that Advicenne considers to be reasonable. However, there can be no assurance that the estimates contained in such forward-looking statements will be verified, which estimates are subject to numerous risks including the risks set forth in the 2024 Universal Registration Document filed with the French financial market authority on April 29, 2025 (a copy of which is available on and to the development of economic conditions, financial markets and the markets in which Advicenne operates. The forward-looking statements contained in this press release are also subject to risks not yet known to Advicenne or not currently considered material by Advicenne. The occurrence of all or part of such risks could cause actual results, financial conditions, performance, or achievements of Advicenne to be materially different from such forward-looking statements. Advicenne expressly declines any obligation to update such forward-looking statements.
Yahoo
an hour ago
- Yahoo
The S&P 500 Index Just Did Something for Only the 5th Time in 50 Years -- History Says a Monumental Move Could Follow
Key Points The S&P 500 recently traded above its 20-day moving average for 60 days. This doesn't happen often. Some trend watchers are optimistic. 10 stocks we like better than S&P 500 Index › The market has been buzzing. After nearly tipping into bear territory in April, the S&P 500 index has stormed all the way back to hit all-time highs and is now up about 8% on the year as of July 23. While volatility has calmed down a bit since President Donald Trump first announced high tariff rates back in April, nothing has been able to slow the market down, despite renewed focus on tariffs, some data indicating the economy is slowing, and increasing concerns about the U.S. government's fiscal situation. In fact, the market just did some for only the fifth time in 50 years, and history says that a monumental move could follow. Can the bull market keep going? As reported by MarketWatch, Ryan Detrick, the chief market strategist at the Carson Group, recently crunched some data and found an interesting stat about the recent performance of the broader benchmark S&P 500. On July 21, the S&P 500 closed above its 20-day moving average for 60 straight days. Investors use moving averages to chart levels that could indicate some kind of breakout, meaning stocks heading higher. It's used more by technical strategists, but can be useful for all investors when it comes to identifying trends or sentiment. The S&P 500 has only achieved this feat four other times dating back to 1975, according to Detrick. The good news for investors following this analysis is that when the market has finished above its 20-day moving average for 60 consecutive days in the past, good things have tended to happen, with the average return between 20% and 26% over the next year. Looking out one month, three months, six months, and a year from this event, there are only a few instances in which the market turned red. "It is what it is, yet another clue this bull market has legs," Detrick wrote in a research note. As of this writing on July 23, the S&P 500 looks to be about 1.9% above its 20-day moving average. History rhymes but rarely repeats When it comes to looking at broader market trends, historical data is a great resource. However, history rarely repeats itself exactly, even if different situations often have parallels. That's why market downturns and recessions usually are unexpected, even when people are constantly worrying and watching. Given the amount of volatility the S&P 500 has experienced this year, it's quite possible the roller-coaster ride continues, and then the market still ends much higher one year from now. After all, the market is still dealing with high uncertainty about tariffs, potential concerns about inflation reigniting, and a potential slowdown of the labor market and economy. So I think investors would be right to remain somewhat cautious and remember that market structure has changed a lot over the past several decades. That said, none of these concerns are exactly new, economic data has largely held up well, and it's possible that Trump's recent "one, big beautiful bill," which includes trillions in tax cuts, continues to propel economic growth, at least in the near term. Ultimately, investors are best off trying to take a long-term view, and not buying into individual stocks trading at meteoric valuations or those detached from fundamentals. The longer one holds their investments, the smaller the chance they have of losing money, and most long-term investors tend to do quite well. Do the experts think S&P 500 Index is a buy right now? The Motley Fool's expert analyst team, drawing on years of investing experience and deep analysis of thousands of stocks, leverages our proprietary Moneyball AI investing database to uncover top opportunities. They've just revealed their to buy now — did S&P 500 Index make the list? When our Stock Advisor analyst team has a stock recommendation, it can pay to listen. After all, Stock Advisor's total average return is up 1,041% vs. just 183% for the S&P — that is beating the market by 858.71%!* Imagine if you were a Stock Advisor member when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $636,628!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,063,471!* The 10 stocks that made the cut could produce monster returns in the coming years. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 21, 2025 Bram Berkowitz has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. The S&P 500 Index Just Did Something for Only the 5th Time in 50 Years -- History Says a Monumental Move Could Follow was originally published by The Motley Fool Sign in to access your portfolio
Business Wire
an hour ago
- Business Wire
Azafaros Announces Initiation of two Global Phase 3 studies with Nizubaglustat in Niemann-Pick disease Type C (NPC) and GM1/GM2 gangliosidoses, respectively
LEIDEN, Netherlands--(BUSINESS WIRE)-- Azafaros, a company focused on developing treatments for the unmet needs of patients with rare lysosomal storage disorders, today announced that the first patient has been dosed in the company's pivotal, multicenter Phase 3 clinical program to evaluate the safety and efficacy of the company's lead asset, nizubaglustat, in patients with Niemann-Pick disease Type C (NPC) and GM1/GM2 gangliosidoses. 'The dosing of the first patient in our Phase 3 program with nizubaglustat is a significant achievement for Azafaros, and a huge step forward in our efforts to bring new, disease modifying treatments to patients with these seriously debilitating diseases,' Share The initiation of the two Phase 3 studies (NCT07054515) represents a major milestone in Azafaros' commitment to addressing the urgent unmet medical needs of children affected by these devastating neurodegenerative disorders. The Phase 3 program consists of two studies targeting the late-infantile and juvenile-onset forms of NPC, and GM1/GM2 gangliosidoses. The studies aim to assess the potential of nizubaglustat to alter disease progression and improve functional outcomes in these patient populations. Today's news follows the recent, successful completion of an oversubscribed series B financing, raising €132M to support the acceleration of nizubaglustat and the expansion of the company's pipeline to other indications. 'The dosing of the first patient in our Phase 3 program with nizubaglustat is a significant achievement for Azafaros and a huge step forward in our efforts to bring new, disease modifying treatments to patients with these seriously debilitating diseases,' said Stefano Portolano, Chief Executive Officer at Azafaros. 'We are deeply grateful to the patients, families, clinicians, and advocacy groups who are partnering with us to advance this promising therapy.' About the NAVIGATE trial The two 18-month randomized 2 to 1, double-blind, placebo-controlled trials will recruit patients at approximately 35 sites across 15 countries worldwide, including in the US, Europe and Latin America. The studies are expected to enroll around 70 patients. The primary endpoint for both trials is the change from baseline to Month 18 in the Scale for the Assessment and Rating of Ataxia (SARA), with both total and functional SARA scores evaluated. For more information on the Phase 3 program, please visit To enquire about trial participation, email: medinfo@ (if a professional) or patientadvocacy@ (if a patient or caregiver). To protect privacy, avoid including identifying information in the initial message. About nizubaglustat Nizubaglustat is a small molecule, orally available and brain penetrant azasugar with a unique dual mode of action, developed as a potential treatment for rare lysosomal storage disorders with neurological involvement, including GM1 and GM2 gangliosidoses and Niemann-Pick disease type C (NPC). Nizubaglustat has received Rare Pediatric Disease Designations (RPDD) for the treatment of GM1 and GM2 gangliosidoses and NPC, Orphan Drug Designations (ODD) for GM1 and GM2 gangliosidosis (Sandhoff and Tay-Sachs Diseases) and NPC, as well as Fast Track Designation and IND clearance for GM1/GM2 gangliosidoses and NPC from the US Food and Drug Administration (FDA). Additionally, nizubaglustat has been awarded Orphan Medicinal Product Designation (OMPD) for the treatment of GM1 and GM2 gangliosidoses by the European Medicines Agency (EMA) and Innovation Passport for the treatment of GM1 and GM2 gangliosidoses from the UK Medicines and Healthcare Products Regulatory Agency (MHRA). About GM1 and GM2 gangliosidoses GM1 gangliosidosis and GM2 gangliosidosis (Tay-Sachs and Sandhoff diseases) are lysosomal storage disorders caused by the accumulation of GM1 or GM2 gangliosides respectively, in the central nervous system (CNS). This results in progressive and severe neurological impairment and premature death. These diseases mostly affect infants and children, and no disease-modifying treatments are currently available. About Niemann-Pick disease Type C (NPC) Niemann-Pick disease Type C is a progressive, life-limiting, neurological, lysosomal storage disorder, caused by mutations in the NPC1 or NPC2 gene and aberrant endosomal-lysosomal trafficking, leading to the accumulation of various lipids, including gangliosides in the CNS. The onset of disease can happen throughout the lifespan of an affected individual, from prenatal life through adulthood. About Azafaros Azafaros is a clinical-stage company founded in 2018 with a deep understanding of rare genetic disease mechanisms using compound discoveries made by scientists at Leiden University and Amsterdam UMC and is led by a team of highly experienced industry experts. Azafaros aims to build a pipeline of disease-modifying therapeutics to offer new treatment options to patients and their families. By applying its knowledge, network and courage, the Azafaros team challenges traditional development pathways to rapidly bring new drugs to the rare disease patients who need them. Azafaros is supported by leading healthcare investors including Forbion, Jeito Capital, Seroba, Pictet Group, BioGeneration Ventures (BGV), BioMedPartners, Asahi Kasei Pharma Ventures, and Schroders Capital.
